Publications by authors named "Max Sung"

Claim this Profile
H
Hepatocellular carcinoma: Epidemiology, diagnosis and treatment.
Ezequiel Mauro, Tiago de Castro, Marcus Zeitlhoefler, Max W Sung, Augusto Villanueva

JHEP Rep· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A multicenter dose-defining/expansion phase 1b study of first-line regorafenib plus pembrolizumab in patients with advanced hepatocellular carcinoma.
Anthony B El-Khoueiry, Richard D Kim, William P Harris, Max W Sung, Dirk Waldschmidt

Hepatology· November 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A Phase 1b Study of Lenvatinib plus Pembrolizumab in Patients with Unresectable Hepatocellular Carcinoma: Extended Analysis of Study 116.
Masatoshi Kudo, Richard S Finn, Masafumi Ikeda, Max W Sung, Ari D Baron

Liver Cancer· August 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Multiplexed immunohistochemical analysis of the immune microenvironment of biliary tract cancers pre- & post-neoadjuvant chemotherapy: case series.
Sirish Dharmapuri, Rafael Cabal, Guray Akturk, Giorgio Ioannou, Sinem Ozbey, Max W Sung

Ann Transl Med· August 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Radioembolization plus Immune Checkpoint Inhibitor Therapy Compared with Radioembolization plus Tyrosine Kinase Inhibitor Therapy for the Treatment of Hepatocellular Carcinoma.
Kirema Garcia-Reyes, Ricki A Gottlieb, Kartikeya M Menon, Vivian Bishay, Rahul Patel, Max W Sung

J Vasc Interv Radiol· May 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Association between treatment-emergent hypertension and survival with lenvatinib treatment for patients with hepatocellular carcinoma in the REFLECT study.
Fabio Piscaglia, Kenji Ikeda, Ann-Lii Cheng, Masatoshi Kudo, Masafumi Ikeda, Max W Sung

Cancer· April 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Impact of underlying liver disease on unresectable hepatocellular carcinoma treated with immune checkpoint inhibitors.
Y Linda Wu, Sarah Cappuyns, Amanda Loh, Sean Sun, Sara Lewis, Max W Sung

BJC Rep· January 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Characterization and Management of Adverse Reactions in Patients With Unresectable Hepatocellular Carcinoma Treated With Lenvatinib.
Anna Jones, Paola Degregorio, Max W Sung, Zahra Ramji, Min Ren

J Adv Pract Oncol· November 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A dose escalation/expansion study evaluating dose, safety, and efficacy of the novel tyrosine kinase inhibitor surufatinib, which inhibits VEGFR 1, 2, & 3, FGFR 1, and CSF1R, in US patients with neuroendocrine tumors.
Arvind Dasari, Erika P Hamilton, Gerald S Falchook, Judy S Wang, Daneng Li, Max W Sung

Invest New Drugs· June 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Molecular Markers of Response to Anti-PD1 Therapy in Advanced Hepatocellular Carcinoma.
Philipp K Haber, Florian Castet, Miguel Torres-Martin, Carmen Andreu-Oller, Marc Puigvehí, Max W Sung

Gastroenterology· January 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Integrated use of PD-1 inhibition and transarterial chemoembolization for hepatocellular carcinoma: evaluation of safety and efficacy in a retrospective, propensity score-matched study.
Brett Marinelli, Edward Kim, Antonio D'Alessio, Mario Cedillo, Ishan Sinha, Max Sung

J Immunother Cancer· June 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Comparative assessment of standard and immune response criteria for evaluation of response to PD-1 monotherapy in unresectable HCC.
Sara Lewis, Mario A Cedillo, Karen M Lee, Octavia Bane, Stefanie Hectors, Max Sung

Abdom Radiol (NY)· March 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
Neoadjuvant cemiplimab for resectable hepatocellular carcinoma: a single-arm, open-label, phase 2 trial.
Thomas U Marron, Maria Isabel Fiel, Pauline Hamon, Nathalie Fiaschi, Edward Kim, Max W Sung

Lancet Gastroenterol Hepatol· March 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Baseline Liver Function and Subsequent Outcomes in the Phase 3 REFLECT Study of Patients with Unresectable Hepatocellular Carcinoma.
Arndt Vogel, Catherine Frenette, Max Sung, Bruno Daniele, Ari Baron

Liver Cancer· September 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Lenvatinib versus sorafenib for first-line treatment of unresectable hepatocellular carcinoma: patient-reported outcomes from a randomised, open-label, non-inferiority, phase 3 trial.
Arndt Vogel, Shukui Qin, Masatoshi Kudo, Yun Su, Stacie Hudgens, Max Sung

Lancet Gastroenterol Hepatol· August 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Safety and efficacy of lenvatinib by starting dose based on body weight in patients with unresectable hepatocellular carcinoma in REFLECT.
Takuji Okusaka, Kenji Ikeda, Masatoshi Kudo, Richard Finn, Shukui Qin, Max Sung

J Gastroenterol· June 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Morphology of tumor and nontumor tissue in liver resection specimens for hepatocellular carcinoma following nivolumab therapy.
Camila C Simoes, Swan N Thung, Maria Isabel Fiel, Max W Sung, Myron E Schwartz

Mod Pathol· April 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A Drosophila platform identifies a novel, personalized therapy for a patient with adenoid cystic carcinoma.
Erdem Bangi, Peter Smibert, Andrew V Uzilov, Alexander G Teague, Sindhura Gopinath, Max Sung

iScience· March 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Mutations in circulating tumor DNA predict primary resistance to systemic therapies in advanced hepatocellular carcinoma.
Johann von Felden, Amanda J Craig, Teresa Garcia-Lezana, Ismail Labgaa, Philipp K Haber, Max W Sung

Oncogene· January 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Safety and Efficacy of Locoregional Treatment during Immunotherapy with Nivolumab for Hepatocellular Carcinoma: A Retrospective Study of 41 Interventions in 29 Patients.
Brett Marinelli, Mario Cedillo, Sara D Pasik, Dudley Charles, Shashi Murthy, Max Sung

J Vasc Interv Radiol· November 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase Ib Study of Lenvatinib Plus Pembrolizumab in Patients With Unresectable Hepatocellular Carcinoma.
Richard S Finn, Masafumi Ikeda, Andrew X Zhu, Max W Sung, Ari D Baron

J Clin Oncol· September 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The effect of radiation therapy on the objective response and outcomes with nivolumab for hepatocellular carcinoma.
William H Smith, Amy S Law, Miriam Hulkower, Heather M McGee, Eric J Lehrer, Max Sung

Acta Oncol· August 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Predictive value of neutrophil to lymphocyte ratio and platelet to lymphocyte ratio in advanced hepatocellular carcinoma patients treated with anti-PD-1 therapy.
Sirish Dharmapuri, Umut Özbek, Jung-Yi Lin, Max Sung, Myron Schwartz

Cancer Med· July 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
First-in-Human Phase I Study of Fisogatinib (BLU-554) Validates Aberrant FGF19 Signaling as a Driver Event in Hepatocellular Carcinoma.
Richard D Kim, Debashis Sarker, Tim Meyer, Thomas Yau, Teresa Macarulla, Max W Sung

Cancer Discov· December 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Correction: Urine protein:creatinine ratio vs 24-hour urine protein for proteinuria management: analysis from the phase 3 REFLECT study of lenvatinib vs sorafenib in hepatocellular carcinoma.
Thomas R Jeffry Evans, Masatoshi Kudo, Richard S Finn, Kwang-Hyub Han, Ann-Lii Cheng, Max W Sung

Br J Cancer· October 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis